文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症肺炎患者下呼吸道检出HHV-7的发生率与临床特征:多中心回顾性研究

Incidence and clinical features of HHV-7 detection in lower respiratory tract in patients with severe pneumonia: a multicenter, retrospective study.
PubMed 文献 · Crit Care · 2023-06-23
一句话结论12中心721例有创机械通气重症肺炎患者中下呼吸道HHV-7阳性率6.24%,阳性与较年轻及CMV、EBV共检出相关,校正后非28天死亡独立危险因素。

本研究为12个医疗中心回顾性研究,纳入2019年1月至2023年3月需有创机械通气并接受支气管肺泡灌液mNGS检测的重症肺炎患者721例,其中下呼吸道HHV-7阳性45例(6.24%)。HHV-7阳性患者较阴性者年轻(59.2岁 vs 64.4岁,p=0.032),巨细胞病毒共检出率更高(42.2% vs 20.7%,p=0.001),EB病毒共检出率更高(35.6% vs 18.2%,p=0.008)。倾向性评分匹配后28天死亡率在阳性与阴性患者间无统计学显著差异(46.2% vs 36.0%,p=0.395)。多因素Cox回归校正性别、年龄和SOFA评分后,HHV-7阳性不是28天死亡的独立危险因素(HR 1.783,95%CI 0.936-3.400,p=0.079)。作者指出该结果可能受样本量相对较小影响。

要点

  • 12中心721例有创机械通气重症肺炎患者中,下呼吸道HHV-7阳性45例(6.24%)。
  • HHV-7阳性者较阴性者年轻(59.2岁 vs 64.4岁,p=0.032),CMV共检出率更高(42.2% vs 20.7%,p=0.001),EBV共检出率更高(35.6% vs 18.2%,p=0.008)。
  • 倾向性评分匹配后,HHV-7阳性与阴性患者28天死亡率无统计学显著差异(46.2% vs 36.0%,p=0.395)。
  • 多因素Cox回归校正性别、年龄、SOFA评分后,HHV-7阳性不是28天死亡的独立危险因素(HR 1.783,95%CI 0.936-3.400,p=0.079)。
  • 作者认为该阴性结果可能受样本量相对较小影响。

适用人群与场景

  • 2019年1月至2023年3月期间,12个医疗中心中需有创机械通气的重症肺炎患者,且接受了支气管肺泡灌洗液商业mNGS检测。

研究设计与关键结果

  • 研究类型为多中心回顾性研究,共纳入12个医疗中心721例需有创机械通气的重症肺炎患者,其中下呼吸道HHV-7阳性45例(6.24%)。
  • HHV-7阳性患者较阴性患者年轻(59.2岁 vs 64.4岁,p=0.032),巨细胞病毒共检出率更高(42.2% vs 20.7%,p=0.001),EB病毒共检出率更高(35.6% vs 18.2%,p=0.008)。
  • 对性别、年龄、ICU入住时SOFA评分及ICU入住至mNGS检测天数进行倾向性评分匹配后,HHV-7阳性与阴性患者28天死亡率无统计学显著差异(46.2% vs 36.0%,p=0.395)。
  • 多因素Cox回归分析校正性别、年龄和SOFA评分后,HHV-7阳性不是28天死亡的独立危险因素(HR 1.783,95%CI 0.936-3.400,p=0.079)。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 局限:作者指出该结果可能受研究样本量相对较小的影响。

对床旁实践的改变

  • 在需有创机械通气的重症肺炎患者中,下呼吸道mNGS检出HHV-7并不少见(6.24%),且常与CMV、EBV共检出,解读结果时应结合共检出病原体综合判断。
  • 本研究提示HHV-7阳性并非28天死亡的独立危险因素(HR 1.783,95%CI 0.936-3.400,p=0.079),作者认为该结果可能受样本量相对较小影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The significance of detecting human herpesvirus 7 (HHV-7) in the lower respiratory tract of patients with severe pneumonia is unclear. This study aims to evaluate the clinical characteristics and prognosis of detecting HHV-7 in the lower respiratory tract of patients with severe pneumonia.

METHODS: Patients with severe pneumonia requiring invasive mechanical ventilation and underwent commercial metagenomic next-generation sequencing (mNGS) testing of bronchoalveolar lavage fluid from January 2019 to March 2023 were enrolled in 12 medical centers. Clinical data of patients were collected retrospectively, and propensity score matching was used for subgroup analysis and mortality assessment.

RESULTS: In a total number of 721 patients, 45 cases (6.24%) were identified with HHV-7 positive in lower respiratory tract. HHV-7 positive patients were younger (59.2 vs 64.4, p = 0.032) and had a higher rate of co-detection with Cytomegalovirus (42.2% vs 20.7%, p = 0.001) and Epstein-Barr virus (35.6% vs 18.2%, p = 0.008). After propensity score matching for gender, age, SOFA score at ICU admission, and days from ICU admission to mNGS assay, there was no statistically significant difference in the 28-day mortality rate between HHV-7 positive and negative patients (46.2% vs 36.0%, p = 0.395). Multivariate Cox regression analysis adjusting for gender, age, and SOFA score showed that HHV-7 positive was not an independent risk factor for 28-day mortality (HR 1.783, 95%CI 0.936-3.400, p = 0.079).

CONCLUSION: HHV-7 was detected in the lungs of 6.24% of patients with severe pneumonia. The presence of HHV-7 in patients with severe pneumonia requiring invasive mechanical ventilation is associated with a younger age and co-detected of Cytomegalovirus and Epstein-Barr virus. While HHV-7 positivity was not found to be an independent risk factor for mortality in this cohort, this result may have been influenced by the relatively small sample size of the study.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Xu J, Zhong L, Shao H, et al. Incidence and clinical features of HHV-7 detection in lower respiratory tract in patients with severe pneumonia: a multicenter, retrospective study. Crit Care. 2023. PMID: 37353839. doi:10.1186/s13054-023-04530-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。